Get the Stockscreener App
1.27
0.79%
-0.01
Prelude Therapeutics Inc stock is traded at $1.27, with a volume of 52,890.
It is down -0.79% in the last 24 hours and up +10.62% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$1.26
Open:
$1.25
24h Volume:
52,890
Relative Volume:
0.25
Market Cap:
$71.88M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.7135
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-14.38%
1M Performance:
+10.62%
6M Performance:
+76.50%
1Y Performance:
-36.06%
1-Day Range:
$1.20
$1.28
1-Week Range:
$1.15
$1.4969
52-Week Range:
$0.6101
$2.01
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.27 | 71.32M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Gap Down & Fast Entry and Exit Trade Plans - newser.com
Can Prelude Therapeutics Incorporated stock maintain operating marginsMarket Risk Summary & Fast Moving Market Watchlists - newser.com
Using Bollinger Bands to evaluate Prelude Therapeutics IncorporatedMarket Sentiment Summary & High Return Trade Opportunity Guides - newser.com
Will Prelude Therapeutics Incorporated stock deliver shareholder value2025 Price Targets & High Return Stock Watch Alerts - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthQuarterly Profit Summary & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-09 05:09:32 - newser.com
Can momentum traders help lift Prelude Therapeutics IncorporatedEarnings Summary Report & AI Driven Price Predictions - newser.com
Using economic indicators to assess Prelude Therapeutics Incorporated potentialFed Meeting & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-09 02:10:25 - newser.com
Analyzing Prelude Therapeutics Incorporated with risk reward ratio charts2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com
CDK4/6 Inhibitor Market Positioned for Remarkable Growth as Revolutionary Therapies Transform Cancer Treatment Landscape in 2024 - Barchart.com
Full technical analysis of Prelude Therapeutics Incorporated stock2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
Will Prelude Therapeutics Incorporated rebound enough to break evenEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Multi asset correlation models including Prelude Therapeutics IncorporatedInsider Buying & Weekly Watchlist for Consistent Profits - newser.com
Will earnings trigger a reversal in Prelude Therapeutics IncorporatedPortfolio Return Summary & Verified Swing Trading Watchlists - newser.com
What drives Prelude Therapeutics Incorporated stock priceSector-Based Investing & Double Digit Trading Ideas - earlytimes.in
Contrasting Cardiol Therapeutics (NASDAQ:CRDL) & Prelude Therapeutics (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) versus Talphera (NASDAQ:TLPH) Financial Contrast - Defense World
3 Promising Penny Stocks With Over $60M Market Cap - simplywall.st
Brokers Set Expectations for PRLD Q3 Earnings - Defense World
Prelude Therapeutics’ (PRLD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates Buy rating on Prelude Therapeutics stock with $5 target - Investing.com Canada
Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRLD, Price Target at $5.00 | PRLD Stock News - GuruFocus
New PROTACs revealed in Prelude Therapeutics patent - BioWorld MedTech
What momentum shifts mean for Prelude Therapeutics IncorporatedInsider Selling & Weekly Return Optimization Plans - newser.com
Will Prelude Therapeutics Incorporated benefit from macro trendsWeekly Trend Summary & Entry Point Confirmation Signals - newser.com
Statistical indicators supporting Prelude Therapeutics Incorporated’s strength2025 Investor Takeaways & Consistent Growth Stock Picks - newser.com
Visual analytics tools that track Prelude Therapeutics Incorporated performance2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
New Highs: Is Prelude Therapeutics Incorporated stock a good pick for beginnersJuly 2025 Review & Consistent Profit Focused Trading Strategies - خودرو بانک
Profit Recap: Will Prelude Therapeutics Incorporated stock go up in YEARWeekly Trade Analysis & Breakout Confirmation Trade Signals - خودرو بانک
Prelude Therapeutics regains Nasdaq compliance with minimum bid price rule - Investing.com Canada
Custom watchlist performance reports with Prelude Therapeutics IncorporatedQuarterly Portfolio Review & Weekly High Potential Alerts - newser.com
How hedge fund analytics apply to Prelude Therapeutics Incorporated stockDip Buying & Long-Term Capital Growth Strategies - newser.com
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):